Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT) in patients implanted with the Resolute Onyx Drug-Eluting Stent (DES) during percutaneous coronary intervention (PCI). Designed to evaluate clinical DAPT outcomes between two DES for the first time ever, the RESOLUTE ONYX ONE-MONTH DAPT Study intends to help inform DAPT guidelines for newer-generation DES that currently favor bare-metal stents (BMS) for patients with stable ischemic heart disease who might require a shorter dual antiplatelet regimen.
August 18, 2017 โ The American Society of Nuclear Cardiology (ASNC) has released a joint expert consensus document with ...
August 17, 2017 โ Cybersecurity has become a growing concern in healthcare as patient data, medical systems and ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Houston Methodist Hospital and Siemens Healthineers have entered into a multi-year agreement to bring cutting-edge technology to Houston Methodist that is not currently available in the Texas Medical Center. This agreement will provide innovative, world-class medical technology to Houston Methodist Hospital and all of its community hospital facilities.
ScImage Inc. was recently awarded a new DIN-PACS IV (Digital Imaging Network/Picture Archiving and Communications System) contract by the U.S. government. The contract is potentially valued up to $400 million, and the terms include one five-year base period and one five-year option period.
There is growing concern among patients and regulators that medical devices, especially implantable electrophysiology ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
August 16, 2017 โ BioCardia Inc. recently announced completion of treatment for the 10-patient roll-in cohort for the ...
August 16, 2017 โ A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) ...
August 16, 2017 โ The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number of ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast agents during MRI scans. Emerging research suggests gadolinium-based contrast agents, injected in a patient's veins to brighten tissues in MRI images, accumulate in the brain. More than 300 million doses of such drugs have been administered since their introduction in 1987.
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug Administration (FDA) in July to initiate a pivotal clinical trial of the SurVeil drug-coated balloon (DCB). The randomized trial will evaluate the SurVeil DCB for treatment for peripheral artery disease (PAD) in the upper leg compared to the Medtronic IN.PACT Admiral DCB.
Aug. 15, 2017 โ Patients undergoing percutaneous coronary intervention (PCI) at safety-net hospitals experienced similar ...
Change Healthcare Cardiology Hemodynamics is an integrated hemodynamic monitoring system for monitoring vital signs and ...
Aug. 15, 2017 โ The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc. (VDI) ...
Aug. 10, 2017 โ The American College of Radiology (ACR) developed three new guidance documents and revised 32 others to ...
Aug. 15, 2017 โ The U.S, Food and Drug Administration (FDA) granted market clearance for the HAART 200 Aortic ...